44 completed, 24 recruiting, 21 unknown, 6 active not recruiting. 51 Not applicable, 9 Phase 1, 8 Phase 4, 5 Phase 2, 3 Phase 3.
Follow Type2diabetes: new trials by email Literature Review of Type2diabetes trials Research Report on Type2diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Caloric Restriction, Hyperglycemic clamp - Type2diabetes | Phase 2 | Not yet recruiting | Adrian Vella | 20 | 2027-12-15 | 2026-10-28 |
| The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans Exendin 9-39, Saline - Genetic Predisposition, Type2diabetes | Phase 2 | Not yet recruiting | Mayo Clinic | 80 | 2026-10-01 | 2026-01-30 |
| CGM Experience, Preferences & Blood Glucose Parameters CGM - Diabete Mellitus, Type2diabetes | Not yet recruiting | Getz Pharma | 75 | 2026-09-10 | 2026-05-26 | |
| Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Endogenex System - Type 2 Diabetes Mellitus, Type2diabetes | Not applicable | Enrolling by invitation | Endogenex, Inc. | 50 | 2026-09-01 | 2026-10-19 |
| Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity Digital Care Community Common Good Program, Usual Care - Type2Diabetes, Hypertension | Not applicable | Recruiting | Chang Gung University of Science and Technology | 169 | 2026-05-12 | 2026-08-21 |
| Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment Progressive Exercise Program (12 Weeks) - Type2diabetes, Mild Cognitive Impairment | Not applicable | Recruiting | The University of Texas Medical Branch, Galveston | 20 | 2026-04-14 | 2026-05-11 |
| Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry) Type 2 Diabetes Mellitus (T2DM), Type2Diabetes | Enrolling by invitation | Endogenex, Inc. | 500 | 2026-03-11 | 2026-07-01 | |
| Integration of a Trained Language Model to Improve Glycemic Control With the My Heart Counts Smartphone App Validation of language model prompts in increasing short-term physical activity, Assessment of long-term changes to physical activity and glycemic control - Type2diabetes | Not applicable | Withdrawn | Stanford University | 2025-07-01 | 2026-08-20 | |
| Understanding and Addressing Risks of Low Socioeconomic Status and Diabetes for Heart Failure Community Champions, Homegrown Heroes - Type2diabetes, Heart Failure | Not applicable | Recruiting | Johns Hopkins University | 156 | 2025-06-20 | 2026-10-14 |
| Use of taVNS for Painful Diabetic Neuropathy: 12-Week Randomized, Sham-Controlled Trial non-invasive transcutaneous vagal nerve stimulation (tVNS), Sham device - Diabetes Mellitus, Diabetic Neuropathies | Not applicable | Completed | Saima Abass Tahammal | 185 | 2025-01-05 | 2026-06-03 |
| Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL - Overweight and Obesity, Type2diabetes | Phase 1 | Completed | Vivani Medical, Inc | 24 | 2024-12-20 | 2025-09-23 |
| Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide - Type2diabetes | Phase 1 | Completed | Lexaria Bioscience Corp. | 148 | 2024-12-04 | 2026-01-12 |
| Effects of High-Intensity Interval Training and Quinoa Supplementation in Women With Type 2 Diabetes High-intensity interval training, Daily quinoa, Combined high-intensity interval training and quinoa consumption - Type2diabetes | Not applicable | Completed | University of Central Lancashire | 32 | 2024-10-16 | 2026-10-07 |
| Motivational Interviewing Applied to Individuals With Diabetes motivational interview - Motivational Interviewing, Stress | Not applicable | Unknown | Bozok University | 66 | 2024-10-15 | 2024-07-17 |
| Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Omarigliptin, Sulphonylureas, Metformin - Type2diabetes | Phase 4 | Unknown | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 938 | 2024-09-01 | 2024-07-16 |
| (DDS) in India: a Screening Tool to Identify Prediabetes and Undiagnosed Type 2 Diabetes in Dental Settings PreDiabetes, Type2diabetes | Unknown | Postgraduate Institute of Dental Sciences Rohtak | 1746 | 2024-09-01 | 2024-06-11 | |
| Exercise Training and Type 2 Diabetes Exercise training - Type2diabetes | Not applicable | Completed | University of the Faroe Islands | 126 | 2024-08-01 | 2024-12-24 |
| Type 2 Diabetes and Blood Brain Barrier Improvement Thiamine, Placebo - Type2diabetes | Early Phase 1 | Recruiting | University of California, Los Angeles | 52 | 2024-08-01 | 2026-03-13 |
| Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients Fuling Yunhua Granules, Dihuang Baoyuan Granules, Fuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placebo - Diabetes Mellitus, Type 2, Diabetes | Phase 2 | Completed | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | 95 | 2024-07-31 | 2026-10-05 |
| Nutrition Outreach and Understanding: Research In Serving Hearts Through Healthy Eating And Tailored Support Medically Tailored Meals - Hypertension, Type2diabetes | Not applicable | Completed | Amanda Shallcross | 75 | 2024-07-30 | 2025-12-05 |
Showing 20 of 101. Sign in to see all of them.
Diabetes Mellitus (20) · Diabetes Mellitus, Type 2 (20) · Obesity (16) · Insulin Resistance (6) · Motor Activity (6) · Hypertension (5) · Heart Failure (4) · Metabolic Syndrome (4) · Diabetes, Gestational (3) · Fatty Liver (3) · Glucose Intolerance (3) · Non-alcoholic Fatty Liver Disease (3) · Overweight (3) · Prediabetic State (3) · Pregnancy in Diabetics (3)
Nutritional and Metabolic Diseases (57) · Metabolic Diseases (50) · Glucose Metabolism Disorders (48) · Endocrine System Diseases (41) · Pathological Conditions, Signs and Symptoms (23) · Diabetes Mellitus (20) · Nutrition Disorders (19) · Signs and Symptoms (19) · Body Weight (18) · Overnutrition (18) · Overweight (15) · Behavior (12) · Cardiovascular Diseases (11) · Hyperinsulinism (10) · Female Urogenital Diseases and Pregnancy Complications (9)
Metformin (5) · dapagliflozin (4) · Exercise (3) · Pioglitazone (3) · Sodium-Glucose Transporter 2 Inhibitors (3) · empagliflozin (3) · Control Groups (2) · Diet, Mediterranean (2) · Insulin Glargine (2) · Tablets (2) · semaglutide (2) · 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine (1) · Anti-Inflammatory Agents (1) · Caloric Restriction (1) · Canagliflozin (1)
Diabetes Foundation, India (5) · Brigham and Women's Hospital (3) · Endogenex, Inc. (3) · Adrian Vella (2) · Medanta, The Medicity, India (2) · Ohio State University (2) · University of Manitoba (2) · University of Michigan (2) · Aalborg University Hospital (1) · All India Institute of Medical Sciences, Bhubaneswar (1) · Amanda Shallcross (1) · Atrogi AB (1) · Ayurai Private Limited (1) · Azienda Ospedaliero Universitaria Maggiore della Carita (1) · Azienda Ospedaliero-Universitaria di Parma (1)
United States (29) · India (10) · China (7) · Turkey (Türkiye) (6) · Australia (5) · Italy (5) · United Kingdom (5) · Germany (4) · Canada (3) · Denmark (3) · Taiwan (3) · Pakistan (2) · South Korea (2) · Sweden (2) · Bangladesh (1)
Anoop Misra, MD (4) · Adrian Vella (2) · Kartik K Venkatesh, MD, PhD (2) · Adrian Vella, MD (1) · Amanda Shallcross (1) · Annamaria Colao, Prof (1) · Chiadi Ndumele, MD, PhD (1) · Christine Field, MD, MPH (1) · Chung-Lieh Hung, MD.PhD (1) · Cody G Durrer, Ph.D. (1) · Daniela Jakubowicz, MD (1) · David Katz, PhD (1) · Deborah O'Connor, PhD, RD (1)
PMID 16718689, PMID 17717720, PMID 17728530, PMID 20101745, PMID 20418179, PMID 20739207, PMID 20876709, PMID 21381068, PMID 21715211, PMID 22830040, PMID 23856989, PMID 23889506, PMID 24146165, PMID 24531328, PMID 24633158, PMID 25251399, PMID 26457582, PMID 26850495, PMID 27710244, PMID 28605608, PMID 28606345, PMID 29562163, PMID 30001381, PMID 30020323, PMID 30415602, PMID 30559238, PMID 30945111, PMID 30990260, PMID 31014938, PMID 31843945, PMID 31912605, PMID 32691606, PMID 32712222, PMID 32759636, PMID 33178196, PMID 33267871, PMID 33352263, PMID 33561280, PMID 33715992, PMID 34861097, PMID 35159232, PMID 36833589, PMID 37164461, PMID 37380728, PMID 38685400, PMID 39395826, PMID 40506207, PMID 4053936, PMID 41240060, PMID 41456635
2023 (2), P30DK020572 (1), P50MD017348 (1), R01DK107680 (1), R01DK116231 (1), R01DK129616 (1), R21AG085268 (1), R21MD016986 (1)